Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile • First Quarter Revenues were $11.9 Billion, increasing 5$4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) • Strengthened Long-Term Growth Profile Through Completion of Karuna Therapeutics, RayzeBio, Mirati Therapeutics, and SystImmune Transacti ...